Abstract
The structural analysis of class B G protein-coupled receptors (GPCR), cell surface proteins responding to peptide hormones, has until recently been restricted to the extracellular domain (ECD). Corticotropin-releasing factor receptor type 1 (CRF1R) is a class B receptor mediating stress response and also considered a drug target for depression and anxiety. Here we report the crystal structure of the transmembrane domain of human CRF1R in complex with the small-molecule antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry. Molecular dynamics and metadynamics simulations on this novel structure and the existing TMD structure for CRF1R provides insight as to how the small molecule ligand gains access to the induced-fit allosteric binding site with implications for the observed selectivity against CRF2R. Furthermore, molecular dynamics simulations performed using a full-length receptor model point to key interactions between the ECD and extracellular loop 3 of the TMD providing insight into the full inactive state of multidomain class B GPCRs.
Keywords: CRF1R, translational non-crystallographic symmetry, molecular dynamics, GPCR, metadynamics, CP-376395.
Graphical Abstract
Current Molecular Pharmacology
Title:Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures
Volume: 10
Author(s): Andrew S. Dore, Andrea Bortolato, Kaspar Hollenstein, Robert K.Y. Cheng, Randy J. Read and Fiona H. Marshall*
Affiliation:
- Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Herts, AL7 3AX,United Kingdom
Keywords: CRF1R, translational non-crystallographic symmetry, molecular dynamics, GPCR, metadynamics, CP-376395.
Abstract: The structural analysis of class B G protein-coupled receptors (GPCR), cell surface proteins responding to peptide hormones, has until recently been restricted to the extracellular domain (ECD). Corticotropin-releasing factor receptor type 1 (CRF1R) is a class B receptor mediating stress response and also considered a drug target for depression and anxiety. Here we report the crystal structure of the transmembrane domain of human CRF1R in complex with the small-molecule antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry. Molecular dynamics and metadynamics simulations on this novel structure and the existing TMD structure for CRF1R provides insight as to how the small molecule ligand gains access to the induced-fit allosteric binding site with implications for the observed selectivity against CRF2R. Furthermore, molecular dynamics simulations performed using a full-length receptor model point to key interactions between the ECD and extracellular loop 3 of the TMD providing insight into the full inactive state of multidomain class B GPCRs.
Export Options
About this article
Cite this article as:
Dore S. Andrew, Bortolato Andrea, Hollenstein Kaspar, Cheng K.Y. Robert, Read J. Randy and Marshall H. Fiona*, Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures, Current Molecular Pharmacology 2017; 10 (4) . https://dx.doi.org/10.2174/1874467210666170110114727
DOI https://dx.doi.org/10.2174/1874467210666170110114727 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adolescent Peer Victimization and PTSD Risk
Adolescent Psychiatry Bacteria From Marine Sponges: A Source of New Drugs
Current Drug Metabolism New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Virtual Screening Against Obesity
Current Medicinal Chemistry Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Pre-Dementia Diagnosis of Alzheimers Disease: Translating Clinicobiologic Research into Practice
Current Psychiatry Reviews Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development
Current Pharmaceutical Design Extruded Product Based on Oat and Fenugreek and their Storage Stability
Current Nutrition & Food Science Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design ERK/MAP Kinase Activation is Evident in Activated Microglia of the Striatum and Substantia Nigra in an Acute and Chronically-Induced Mouse Model of Parkinson’s Disease
Current Neurovascular Research Fostering Resilience: Protective Agents, Resources, and Mechanisms for Adolescent Refugees' Psychosocial Well-Being
Adolescent Psychiatry Zacopride Exerts an Antiarrhythmic Effect by Specifically Stimulating the Cardiac Inward Rectifier Potassium Current in Rabbits: Exploration of a New Antiarrhythmic Strategy
Current Pharmaceutical Design Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Current Neuropharmacology Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
CNS & Neurological Disorders - Drug Targets Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Current Alzheimer Research HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism UV Induced Skin Immunosuppression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry